VERU INC. (The Female Health Company) - 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for The Female Health Company (VERU Inc.) for the three-month period ended December 31, 2008. The Company manufactures, markets, and distributes the FC1 and FC2 female condoms, the only FDA-approved products under a woman's control for preventing unintended pregnancy and sexually transmitted diseases (including HIV/AIDS). The Company operates manufacturing facilities in London, England (FC1) and Selangor, Malaysia (FC2), with sales in 116 countries.
Key Financial Metrics
| Metric | Q1 2009 (Ended Dec 31, 2008) | Q1 2008 (Ended Dec 31, 2007) |
|---|---|---|
| Net Revenues | $5,344,838 | $5,734,751 |
| Gross Profit | $2,441,194 | $2,366,116 |
| Gross Margin | 45.7% | 41.3% |
| Operating Income | $438,935 | $729,645 |
| Net Income | $1,633,391 | $854,611 |
| Net Income Attributable to Common Stockholders | $1,608,816 | $813,968 |
| Diluted EPS | $0.06 | $0.03 |
| Cash Provided by Operating Activities | $3,445,791 | $1,289,043 |
| Cash and Restricted Cash (End of Period) | $3,364,811 | $1,604,306 |
| Total Assets | $12,012,316 | $13,830,738 |
| Total Liabilities | $3,304,233 | $4,121,536 |
| Stockholders' Equity | $8,708,083 | $9,709,202 |
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 7% ($389,913) primarily due to a higher sales mix of the lower-priced FC2 product compared to FC1.
- Profitability Increase: Despite lower revenue, Net Income increased 91% ($778,780). This was driven by a significant non-operating foreign currency transaction gain of $1,194,107 (compared to $115,358 in the prior year) resulting from the strengthening of the U.S. dollar against the British pound and the Malaysian ringgit.
- Operating Expenses: Operating income decreased 40% due to a 25% increase in Selling, General, and Administrative (SG&A) expenses. SG&A rose due to higher compensation costs, Sarbanes-Oxley consulting fees, and one-time costs related to the FC2 FDA approval process.
- Cash Flow: Operating cash flow more than doubled to $3.4 million, aided by a significant reduction in accounts receivable ($3.4 million decrease) due to timing of shipments and collections.
- Stock Repurchases: The Company repurchased 458,400 shares of common stock during the quarter for approximately $1.4 million, leaving 700,600 shares remaining under the current repurchase program.
Guidance, Outlook, and Risks
- FC2 FDA Approval: The FDA's OB/GYN Device Advisory Committee unanimously recommended approval of the FC2 female condom in December 2008 with a single condition regarding labeling. The Company is finalizing package labeling and directions. Approval is expected to enable procurement by USAID for global prevention programs.
- Market Strategy: The Company continues to focus on public sector distribution (UNAIDS, USAID) and expanding commercial partnerships. FC2 is positioned as a more cost-effective alternative to FC1.
- Liquidity: Management believes current cash ($3.2 million) is adequate for near-term operations. The Company has a $1.5 million revolving credit facility with Heartland Bank, with no amounts outstanding as of December 31, 2008.
- Risks:
- Single Product Reliance: The Company derives virtually all revenue from female condoms.
- Foreign Currency: Manufacturing costs are in GBP and MYR, while sales are often in USD. Fluctuations significantly impact reported earnings (as seen in the $1.2M gain this quarter).
- Regulatory: Continued compliance with FDA regulations is critical; failure could result in withdrawal of approval.
- Capital Needs: The Company may need to raise additional capital to fund working capital and promotional expenditures.
Investor Verification Checklist
- FC2 FDA Status: Verify the final FDA approval status of the FC2 product and the specific labeling conditions required.
- Currency Sensitivity: Assess the sustainability of earnings given the heavy reliance on foreign currency translation gains/losses rather than core operating margin expansion.
- Accounts Receivable: Confirm the trend in Days Sales Outstanding (DSO) to ensure the Q1 2009 reduction was due to timing rather than a permanent shift in collection efficiency.
- Stock Repurchase Program: Monitor the remaining 700,600 shares available for repurchase and the Company's cash burn rate relative to its $3.2 million cash balance.
- Public Sector Contracts: Review upcoming renewals of agreements with UNAIDS and USAID, which are critical to revenue stability.